After a Fogarty Fellowship at the NIH, Dr. Dropulić joined the faculty at Johns Hopkins University developing Lentiviral vectors as delivery systems for gene therapy. He has founded many companies, including ViRxSys, which demonstrated the safety of Lentiviral vectors in humans, and Lentigen, which developed the Lentiviral vector used to produce Kymriah™, the first FDA-approved gene therapy product. In order to integrate Lentiviral vector technology with closed-system automated cell processing devices to enable distributive place-of-care manufacturing, Dr. Dropulić spearheaded the acquisition of Lentigen by Miltenyi Biotec, where he led the development of a global place-of-care network of clinical centers that were able to successfully manufacture CAR-T cell products and demonstrate their therapeutic benefits in clinical trials. Dr. Dropulić is the co-founder and executive director of Caring Cross, a non-profit that strives to develop improved business models to support the affordability and accessibility of gene therapy products.